New hope for Tough-to-Treat blood cancer: trial tests powerful drug trio
NCT ID NCT07255963
Summary
This study is testing a new combination of three drugs—pirtobrutinib, lisaftoclax, and rituximab—for people with an aggressive type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has come back or stopped responding to previous treatments. The goal is to see if this three-drug approach is safe and can effectively shrink or eliminate the cancer. The study will enroll about 29 adults who have had at least one prior treatment for their lymphoma.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DLBCL - DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215006, China
Conditions
Explore the condition pages connected to this study.